Genentech Breast BO45853
Brief Summary
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
Official Title
A Phase II, Open‑Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early‑Stage, PIK3CA‑Mutated Breast Cancer (NCT07054190)
Conditions
Breast Cancer
